Form 4 for AKBA Akebia Therapeutics, Inc.
Accepted 2023-03-01 00:00:00 ET · period of report 2023-02-27 · accession 0001562180-23-002040 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 2023-03-01 | 2023-02-27 | AKBA | Burke Steven Keith | SVP, Chief Medical Off | S - Sale | $0.81 | -7,539 | 608.2K | -1% | -$6,107 |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Stock | 2023-02-27 | S | D | 7,539 | $0.81 | 608,177 | D | — | — | (F1) This sale was made automatically by the Issuer to cover tax withholding obligations in connection with the vesting and settlement of one-third of the reporting person's restricted stock units granted on February 26, 2021. |